Escharotomy Incisions 17
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
Examination of the Spine
Page 1 of 7 Examination of the Spine Neck and back pain are common presentations in primary care. Many cases of neck and back pain are due to benign functional or postural causes but a thorough history and examination is essential to assess the cause (see articles Low Back Pain and Sciatica, Thoracic Back Pain and Neck Pain), any associated psychological difficulties (eg depression, anxiety or somatisation disorder), and any functional impairment, including restrictions with work, leisure and domestic activities. General examination of the spine The examination should begin as soon as you first see the patient and continues with careful observation during the whole consultation. It is essential to observe the patient's gait and posture. Inconsistency between observed function and performance during specific tests may help to differentiate between physical and functional causes for the patient's symptoms. Inspection Examination of any localised spinal disorder requires inspection of the entire spine. The patient should therefore undress to their underwear. Look for any obvious swellings or surgical scars. Assess for deformity: scoliosis, kyphosis, loss of lumbar lordosis or hyperlordosis of the lumbar spine. Look for shoulder asymmetry and pelvic tilt. Observe the patient walking to assess for any abnormalities of gait. Palpation Palpate for tenderness over bone and soft tissues. Perform an abdominal examination to identify any masses, and consider a rectal examination (cauda equina syndrome may present with low back pain, pain in the legs and unilateral or bilateral lower limb motor and/or sensory abnormality, bowel and/or bladder dysfunction with saddle and perineal anaesthesia, urinary dysfunction and bowel disturbances, and rectal examination may reveal loss of anal tone and sensation). -
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. -
Harbor Chiropractic, P.C
American Arbitration Association New York No-Fault Arbitration Tribunal In the Matter of the Arbitration between: Harbor Chiropractic, P.C. AAA Case No. 17-18-1084-8145 (Applicant) Applicant's File No. 113141 - and - Insurer's Claim File No. 0397235870 NAIC No. 19232 Allstate Insurance Company (Respondent) ARBITRATION AWARD I, James Hogan, the undersigned arbitrator, designated by the American Arbitration Association pursuant to the Rules for New York State No-Fault Arbitration, adopted pursuant to regulations promulgated by the Superintendent of Insurance, having been duly sworn, and having heard the proofs and allegations of the parties make the following AWARD: Injured Person(s) hereinafter referred to as: EIP 1. Hearing(s) held on 04/18/2019, 06/19/2019 Declared closed by the arbitrator on 04/18/2019 Michael Spector from The Odierno Law Firm P.C. participated in person for the Applicant Allison Lindsey from Law Offices Of Karen L Lawrence participated in person for the Respondent 2. The amount claimed in the Arbitration Request, $ 4,241.52, was AMENDED and permitted by the arbitrator at the oral hearing. At the hearing, the Applicant amended the amount in controversy to $2,778.45 to be in accordance with the Chiropractic Fee Schedule for both the CMT and physical medicine services provided on the 18 DOS, but also to be in accordance with the fee schedule for the range of motion testing and manual muscle testing. Stipulations WERE NOT made by the parties regarding the issues to be determined. 3. Summary of Issues in Dispute The EIP, a 27 year old female, was injured in a collision on 12/30/15. -
Journal Pre-Proof
Mayo Clinic Proceedings Telemedicine Musculoskeletal Examination The Telemedicine Musculoskeletal Examination Edward R. Laskowski, MD; Shelby E. Johnson, MD; Randy A. Shelerud, MD; Jason A. Lee, DO; Amy E. Rabatin, MD; Sherilyn W. Driscoll, MD; Brittany J. Moore, MD; Michael C. Wainberg, DO; Carmen M. Terzic, MD, PhD All authors listed are members of the Department of Physical Medicine and Rehabilitation, Mayo Clinic Rochester, and additionally, Dr. Laskowski and Dr. Lee are members of the Division of Sports Medicine of the Department of Orthopedics, Mayo Clinic Rochester. Corresponding Author: Edward R. Laskowski, MD Physical Medicine and Rehabilitation Mayo Clinic 200 First Street SW Rochester, MN 55905 [email protected] Abstract Telemedicine uses modern telecommunication technology to exchange medical information and provide clinical care to individuals at a distance. Initially intended to improve health care to patients in remote settings, telemedicine now has a broad clinical scope with the generalJournal purpose of providing Pre-Proofconvenient, safe, time and cost-efficient care. The Corona Virus Disease 2019 (COVID-19) pandemic has created significant nationwide changes to health care access and delivery. Elective appointments and procedures have been cancelled or delayed, and multiple states still have some degree of shelter-in-place orders. Many institutions are now relying more heavily on telehealth services to continue to provide medical care to individuals while also preserving the © 2020 Mayo Foundation for Medical Education and Research. Mayo Clin Proc. 2020;95(x):xx-xx. Mayo Clinic Proceedings Telemedicine Musculoskeletal Examination safety of healthcare professionals and patients. Telemedicine can also help reduce the surge in health care needs and visits as restrictions are lifted. -
L:\0901 with Peru\0901PHARMAPPX.Wpd
Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6 -
Abstract Acute Emetic Responses to Seven Cancer Chemotherapeutic
Emesis Induced by Cancer Chemotherapeutic Agents in the Suncus Murinus: A New Experimental Model Norio MATSUKI, Shinya UENO, Takahide KAJI, Akane ISHIHARA, Chao-Hsiung WANG k and Hiroshi SAITO Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo 113, Japan Chia-nan Junior College of Pharmacy, Tainan Hsien, Taiwan Accepted September 1, 1988 Abstract Acute emetic responses to seven cancer chemotherapeutic agents (adriamycin, bleomycin, cisplatin, cyclophosphamide, 5-fluorouracil, methotrexate, mitomycin C) were studied in the Suncus murinus. Intravenous injection of the drugs caused vomiting with various latency. Cisplatin-induced emesis was prevented by the pretreatment with metoclopramide or chlorpromazine but not with domperidone. These results indicate that the Suncus murinus is a useful animal for testing emetic activities of cancer chemotherapeutics and antiemetic activities of prophylactic drugs. Nausea and vomiting, although rarely life threatening, are painful side effects for the patients who receive cancer chemotherapy (1). However, developments of less emetic chemotherapeutic agents and antiemetic drugs are difficult because only a few mammals vomit in response to emetic drugs. The smallest mammal currently available for these purposes is the ferret (2,3), but its body weight is more than 1 kg. If we could use smaller mammals, it would be easier to test various agents for emetic and antiemetic activities. Recently we have shown that the Suncus murinus (house musk shrew), a species of insectivora, vomit in response to various emetic drugs (4) or motion stimulus (5). However, it is not known whether cancer chemotherapeutics induce emesis in the suncus. In the present study emetic response to several chemotherapeutics were investigated in the suncus for its use as a new animal model for emesis testing. -
1996 Medical Impairment Guidelines
STATE OF NEW YORK WORKERS' COMPENSATION BOARD MEDICAL GUIDELINES June 1996 David A. Paterson, Governor Robert E. Beloten, Chair TABLE OF CONTENTS FOREWORD ..................................................................................................................................vii INTRODUCTION ............................................................................................................................. 1 A. ROLE OF EXAMINING HEALTH PROVIDERS................................................................ 2 B. ROLE OF THE WORKERS' COMPENSATION LAW JUDGE .......................................... 2 C. DISABILITY EVALUATION IN WORKERS' COMPENSATION CASES. ............... 2 Review of the Claimant's File......................................................................................... 3 1. TYPES OF DISABILITY UNDER THE WORKERS' COMPENSATION LAW ................................................................................................. 3 2. TYPES OF FINAL EVALUATION EXAMINATION .................................................. 3 Schedule Awards ........................................................................................................... 4 Non-Schedule Awards....................................................................................................5 I. EXTREMITIES.............................................................................................................................. 6 A. UPPER EXTREMITIES.........................................................................................................6 -
Stembook 2018.Pdf
The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. -
PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
Harmonized Tariff Schedule of the United States (2010) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2010) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. -
List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify
List of Psychoactive Drug Spirits for MD A-Methylfentanyl, Abilify, abnormal basal ganglia function, abuse of medicines, Aceperone, Acepromazine, Aceprometazine, Acetildenafil, Aceto phenazine, Acetoxy Dipt, Acetyl morphone, Acetyl propionyl morphine, Acetyl psilocin, Activation syndrome, acute anxiety, acute hypertension, acute panic attacks, Adderall, Addictions to drugs, Addictions to medicines, Addictions to substances, Adrenorphin, Adverse effects of psychoactive drugs, adverse reactions to medicines, aggression, aggressive, aggressiveness, agitated depression, Agitation and restlessness, Aildenafil, Akuammine, alcohol abuse, alcohol addiction, alcohol withdrawl, alcohol-related brain damage, alcohol- related liver damage, alcohol mix with medicines for adverse reaction, Alcoholism, Alfetamine, Alimemazine, Alizapride, Alkyl nitrites, allergic breathing reactions to meds, choking to anaphallectic shock, & death; allergic skin reactions to meds, rash, itchyness, hives, welts, etc, Alletorphine, Almorexant, Alnespirone, Alpha Ethyltryptamine, Alpha Neoendorphin, alterations in brain hormones, alterations in mental status, altered consciousness, altered mind, Altoqualine, Alvimopan, Ambien, Amidephrine, Amidorphin, Amiflamine, Amisulpride, Amphetamines, Amyl nitrite, Anafranil, Analeptic, Anastrozole, Anazocine, Anilopam, Antabuse, anti anxiety meds, anti dopaminergic activity, anti seizure meds, Anti convulsants, Anti depressants, Anti emetics, Anti histamines, anti manic meds, anti parkinsonics, Anti psychotics, Anxiety disorders, -
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7